Fierce Pharma October 18, 2023
UCB has been “eagerly awaiting” FDA approval for its psoriasis therapy Bimzelx (bimekizumab) after manufacturing problems resulted in a rejection last May. Now, the wait is over.
The med is the first psoriasis treatment that works by selectively inhibiting interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines that play a hand in the inflammatory process, according to a UCB release. The approval covers the treatment of moderate-to-severe plaque psoriasis in adults who qualify for systemic therapy or phototherapy.
In phase 3 trials, Bimzelx proved its worth against placebo and the popular psoriasis drugs AbbVie’s Humira and Johnson & Johnson’s Stelara. Across all studies, 85% to 91% of Bimzelx-treated patients achieved clear or almost clear skin by week 16,...
Today's Sponsors
Today's Sponsor